The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study.
 
Eric Christenson
Honoraria - OncLive
Consulting or Advisory Role - Seres Therapeutics
Research Funding - Affimed Therapeutics
(OPTIONAL) Uncompensated Relationships - Haystack Oncology
 
Su Jin Lim
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Anna Ferguson
No Relationships to Disclose
 
Rose Parkinson
No Relationships to Disclose
 
Yvette Cetasaan
No Relationships to Disclose
 
Christina Rodriguez
No Relationships to Disclose
 
Richard Burkhart
No Relationships to Disclose
 
Ana De Jesus-Acosta
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Jin He
No Relationships to Disclose
 
Rachel B. Klein
No Relationships to Disclose
 
Kelly Lafaro
No Relationships to Disclose
 
Dan Laheru
No Relationships to Disclose
 
Dung T. Le
Stock and Other Ownership Interests - Seagen
Honoraria - Merck
Consulting or Advisory Role - Bristol-Myers Squibb; HalioDX; Janssen; Merck; Nouscom
Research Funding - Abbvie (Inst); Aduro Biotech; Bristol-Myers Squibb; Curegenix; Medivir; Merck; Nouscom (Inst)
Patents, Royalties, Other Intellectual Property - Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".
 
Christopher Shubert
Honoraria - Fujifilm
Consulting or Advisory Role - Exelixis
 
Neeha Zaidi
Consulting or Advisory Role - HalioDx; Ipsen
 
Elizabeth M. Jaffee
Stock and Other Ownership Interests - ABMETA Therapeutics
Consulting or Advisory Role - Achilles Therapeutics; Adaptive Biotechnologies; BlueDot; Candel Therapeutics; Carta; Dragonfly Therapeutics; Genocea Biosciences; Medically Home; NextCure
Research Funding - Bristol-Myers Squibb; Roche
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
 
William Burns
No Relationships to Disclose
 
Amol Narang
Research Funding - Boston Scientific
 
Lei Zheng
Stock and Other Ownership Interests - Alphamab; Mingruizhiyao; Z and L International Medical
Consulting or Advisory Role - Alphamab; Ambrx; AstraZeneca; BioArdis; Biosynergies; Coherent; datarevive; Foundation Medicine; Johnson & Johnson/Janssen; Merck; Merrimack; Mingruizhiyao; NovaGenesis; novarock; Snow Lake Capital; Xilio Therapeutics
Research Funding - Amgen; AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Gradalis; Halozyme; InxMed; ITeos Therapeutics; Merck; NovaRock
Patents, Royalties, Other Intellectual Property - GVAX, licensed to Aduro Biotech.
Other Relationship - QED Therapeutics